Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Rhizophora mucronata stem extract is a botanical preparation derived from the loop-root mangrove tree. Methanol extracts of the stem have been found to contain a variety of bioactive phytochemicals, including alkaloids, flavonoids, and steroids. In vitro pharmacological studies have demonstrated that the extract possesses selective antineoplastic activity, showing significant cytotoxicity against colon (CaCo-2), breast (MCF-7), lung (A549), and prostate (PC-3) cancer cell lines. Notably, the extract appears to be non-toxic to normal human lung fibroblast cells (WI-38) at therapeutic concentrations. The anticancer effects are attributed to the synergistic action of its secondary metabolites, which may inhibit cell viability and potentially induce apoptosis, although the precise molecular targets are still under investigation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on rhizophora mucronata stem extract.